ATE439853T1 - Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin - Google Patents

Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin

Info

Publication number
ATE439853T1
ATE439853T1 AT03777001T AT03777001T ATE439853T1 AT E439853 T1 ATE439853 T1 AT E439853T1 AT 03777001 T AT03777001 T AT 03777001T AT 03777001 T AT03777001 T AT 03777001T AT E439853 T1 ATE439853 T1 AT E439853T1
Authority
AT
Austria
Prior art keywords
antitrypsin
composition
diluent
carrier
protease inhibitor
Prior art date
Application number
AT03777001T
Other languages
English (en)
Inventor
Ian C Bathurst
Philip A Pemberton
David J Sundin
James W Mayhew
Arturo J Angel
Philip J Barr
Original Assignee
Arriva Prometic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arriva Prometic Inc filed Critical Arriva Prometic Inc
Application granted granted Critical
Publication of ATE439853T1 publication Critical patent/ATE439853T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782—Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03777001T 2002-11-20 2003-11-20 Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin ATE439853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42770202P 2002-11-20 2002-11-20
PCT/GB2003/005049 WO2004045634A1 (en) 2002-11-20 2003-11-20 Composition and method for treating inflammatory diseases using protease inhibitors

Publications (1)

Publication Number Publication Date
ATE439853T1 true ATE439853T1 (de) 2009-09-15

Family

ID=32326583

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03777001T ATE439853T1 (de) 2002-11-20 2003-11-20 Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin

Country Status (9)

Country Link
US (1) US20080095806A1 (de)
EP (1) EP1562621B1 (de)
JP (1) JP2006508971A (de)
AT (1) ATE439853T1 (de)
AU (1) AU2003286258B2 (de)
CA (1) CA2506839A1 (de)
DE (1) DE60328909D1 (de)
ES (1) ES2330516T3 (de)
WO (1) WO2004045634A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510657A (ja) * 2002-12-06 2006-03-30 アライバ ファーマシューティカルズ，インコーポレイティド 中耳炎の処置のための方法および組成物
WO2004096113A2 (en) * 2003-04-28 2004-11-11 Medical Instill Technologies, Inc. Container with valve assembly for filling and dispensing substances, and apparatus and method for filling
US7217690B2 (en) 2003-10-07 2007-05-15 Kimberly-Clark Worldwide, Inc. Compositions of sunflower trypsin inhibitors
WO2005117955A1 (en) * 2004-05-19 2005-12-15 Arriva Pharmaceuticals, Inc. Treatment of atopic dermatitis with unglycosylated alpha one-antitrypsin
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7468350B2 (en) 2004-06-16 2008-12-23 Pneumrx, Inc. Glue composition for lung volume reduction
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
JP2006176461A (ja) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd 粒状物
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
EP1976531B1 (de) * 2006-01-06 2011-11-09 Ed. Geistlich Söhne AG für Chemische Industrie Bestrahlte zusammensetzungen und behandlung von krebs mit strahlung in kombination mit taurolidin und/oder taurultam
WO2007127286A2 (en) 2006-04-24 2007-11-08 Medical Instill Technologies, Inc. Needle penetrable and laser resealable lyophilization device and related method
CN101977626A (zh) 2008-01-21 2011-02-16 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
CN102316730A (zh) * 2008-05-09 2012-01-11 天雅瑞药业有限公司 用于减轻全身性炎症和/或血管炎症的n-乙酰半胱氨酸(nac)的控释
US20100022652A1 (en) * 2008-07-28 2010-01-28 Tyco Healthcare Group Lp Antimicrobial and Anticoagulant Compositions and Methods
ES2332645B1 (es) 2009-06-30 2010-10-18 Grifols, S.A. Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.
CA2779147A1 (en) * 2009-10-28 2011-05-12 Eugene B. Guthery Rosacea topical skin treatment method and formulation
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
WO2012029061A2 (en) * 2010-08-31 2012-03-08 Uri Wormser POLYPEPTIDES DERIVED FROM α-1 ANTITRYPSIN AND METHODS OF USE THEREOF
CA2873655C (en) * 2012-05-14 2021-04-06 Teijin Limited Radiation sterilization-resistant protein composition
JP6105252B2 (ja) * 2012-10-26 2017-03-29 株式会社コーセー 皮膚内挙動評価方法
US9593339B1 (en) * 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2019118330A1 (en) * 2017-12-12 2019-06-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Thermoresponsive hydrogel containing polymer microparticles for controlled drug delivery to the ear
CN109223707B (zh) * 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途
US12342819B2 (en) * 2019-08-23 2025-07-01 The Hong Kong University Of Science And Technology Elasnin, a bacteriostatic agent that has potent antibiofilm activities against both mono- and multi-species biofilm
WO2022072842A1 (en) * 2020-10-01 2022-04-07 Microbion Corporation Methods of treating bone infections
CN113173970B (zh) * 2021-06-15 2022-11-15 北京林业大学 一种核桃粕抗炎肽fpl及其应用
AU2024231427A1 (en) * 2023-03-09 2025-09-04 Merck Sharp & Dohme Llc Formulations comprising actriia polypeptide variants

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57145817A (en) * 1981-03-05 1982-09-09 Satoru Yamazaki Remedy for peptic ulcer
US4816449A (en) * 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US5026686A (en) * 1989-02-01 1991-06-25 Washington University Antiviral peptides
CS275231B2 (en) * 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
ATE146970T1 (de) * 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
US5346886A (en) * 1993-11-15 1994-09-13 John Lezdey Topical α-1-antitrypsin, non-aqueous lipid miscible, benzalkonium chloride compositions for treating skin
GB2318732A (en) * 1996-11-01 1998-05-06 Johnson & Johnson Medical Wound healing compositions containing alpha-1-antitrypsin
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6344189B1 (en) * 1998-04-01 2002-02-05 Biotech Australia Pty., Ltd. Use of protease inhibitors for treating skin wounds
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6096327A (en) * 1998-11-05 2000-08-01 Protease Sciences Inc. Cosmetic compositions containing human type serine protease inhibitors for revitalizing the skin
AU1101501A (en) * 1999-10-27 2001-05-08 K-Quay Enterprises, Llc Methods and compositions for treatment of keratoconus using protease inhibitors
US6627785B1 (en) * 2000-02-29 2003-09-30 Virginia Commwealth University Wound dressings with protease-lowering activity

Also Published As

Publication number Publication date
ES2330516T3 (es) 2009-12-11
DE60328909D1 (de) 2009-10-01
CA2506839A1 (en) 2004-06-03
US20080095806A1 (en) 2008-04-24
EP1562621A1 (de) 2005-08-17
AU2003286258A1 (en) 2004-06-15
EP1562621B1 (de) 2009-08-19
AU2003286258B2 (en) 2006-12-21
WO2004045634A1 (en) 2004-06-03
JP2006508971A (ja) 2006-03-16

Similar Documents

Publication Publication Date Title
ATE439853T1 (de) Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
BR0312275A (pt) Composição e método para tratamento de superfìcies ou de ar, superfìcie assim tratada e artigo de manufatura
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
DE60117605D1 (de) Thiazolyl-inhibitoren von tyrosinkinasen der tec-familie
SE0201980D0 (sv) Novel compounds
PL370134A1 (en) Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
BR0317715A (pt) Composições e processos de uso de collajolie
DE50207442D1 (de) Behandlung der akne mit lipoxygenase inhibitoren
NO972538L (no) Nye sulfonamider
ATE353880T1 (de) Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate
NO20002958L (no) Benzamidinderivater som koagulasjonsfaktor Xa-hemmere
NO20005889D0 (no) Benzimidazolanaloger som ned-regulatorer av IgE
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
SE9602263D0 (sv) New amino acid derivatives
DE69031656D1 (de) Saccharinderivate zur verwendung als proteolytische enzyminhibitoren sowie verfahren zur herstellung
DE60026279D1 (de) Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i
MXPA05004384A (es) Piperacinil y diacepanil benzamidas y benztioamidas.
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
SE0201977D0 (sv) Novel compounds
BR0212535A (pt) Compostos e composições como inibidores de catepsina
ATE443044T1 (de) Tace inhibitoren
YU49422B (sh) Upotreba inhibitora ugljenične anhidraze za proizvodnju medikamenata za tretiranje makularnog edema ili makularne degeneracije izazvane starošću
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
BR0308170A (pt) Composição para limpeza lìquida aquosa, método para limpeza de um substrato, e, uso de um polioxometalato
ATE218877T1 (de) Bowman-birk-inhibitorzusammensetzungen zur behandlung von entzündungskrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties